A method of treating inflammatory diseases of the pelvic organs mycoplasma-herpetic etiology

 

(57) Abstract:

The invention relates to medicine and can be used in the treatment of concomitant chlamydial herpes infection in women with inflammatory diseases of the pelvic organs (PID). Proposed treatment to include a preliminary immunotherapy complex immunoglobulin preparation with-2-recombinant interferon in the form of candles for 7-10 days, antiviral drugs since 3-4 days immunotherapy for 4-5 days 5-6 day - introduction of antibiotics within 6-10 days; at the same time hormonotherapy from 5 to 25 days of the menstrual cycle for 3-6 months. The method allows to increase the effectiveness of treatment, to reduce the treatment time, increase miracidium period.

The invention relates to medicine and can be used in the treatment of concomitant chlamydial herpes infection in women with inflammatory diseases of the pelvic organs.

In recent times among sexually transmitted infections (STIs) increases the frequency of Mycoplasma-virus associations in patients with inflammatory diseases of the pelvic organs (PID).

Concomitant chlamydial herpes is lady subjective and objective symptoms, characteristic of non-specific PID. Moreover, inflammatory processes are chronic and subacute nature of the flow.

In persons with chlamydial herpetic infection, the immune system is functioning inadequately. A full immune response is not formed or is formed too slowly, or over protective immune responses dominated by immunopathological.

When co-infection of cell cultures at the forefront of the competitive relationship between microorganisms for life "territory". This contributes not only to adapt chlamydia and herpes simplex virus (HSV) to intracellular parasitic, but also enhances the pathogenic properties of each of the followers of this Association, which leads to greater resistance of microorganisms to external influences, including antibiotics.

In venereal practice mostly used methods of treating monoinfected with etiopathogenetic approach.

There is a method of treatment of chlamydial infection of the urogenital tract in women, providing hormone therapy drug triquilar-28 during the menstrual cycle, with subsequent joint hormone and antibioticotherapy the treatment of chlamydial infection of the urogenital tract in women with reproductive dysfunction, where are hormonecoral estrogen and progestogen, followed by a combination of antibiotics subendometrial and orally for 7-10 days with simultaneous application of proteolytic enzymes in a solution of dimethylsulfoxide method phonophoresis. [Pat. RF 2114622, a 61 K 31/65, 38/24, 10.07.98, bull. 19].

There is a method of treatment of chlamydial infection of the urogenital tract in women through a combination antibiotic therapy with reception of immunopreparatov using aktovegin local and intramuscularly. [Pat. RF 2108104, a 61 K 35/14, from 10.04.98, bull. 10].

For the treatment of herpes recently widely used drug acyclovir. [STDs, 2, 1995, S. 11-17, 48-49].

With recurrent genital herpes investigated the effectiveness of long-term suppressive therapy (5 years) aciclovir. Despite the positive results of the study cannot be regarded as sufficient effectiveness to cure, as it does not exclude the possibility of resistance to the drug. This is due to tissue tropism, the ability of herpes viruses to multiply in infected cells and life preservation in implicit morphological and immunochemical modified f is militay vaccine, followed by the introduction of Dibazol and Siberian ginseng. Period of issue is 1.5-2.0, the Course of treatment is 10 months. [A. S. USSR 1139436, a 61 K 31/00, from 15.02.85, bull. 6]. The method is time-consuming and does not provide intracellular inhibition of viral replication as vaccination knowingly infected person is unable qualitatively alter the immune status.

There is a method of herpes treatment that includes 3 stages.

In the acute stage of infection or recurrence of the use of acyclovir interior and local in combination with antioxidants (vitamins C, E), inducers of interferon (Reaferon), inhibitors of prostaglandin (indomethacin).

In remission, the use of immunomodulators (neovir, Dibazol), adaptogens (Magnolia, Golden root).

2 months after the end of therapy - vaccination. [Safronova M. M. Principles of diagnosis and treatment of genital herpes. Clinical pharmacology and therapeutics, 1998, 1].

The method is time-consuming and complicated, moreover, does not provide inhibition of intracellular multiplication of infection.

A pronounced therapeutic effect showed a diagram of the combined use of 2-interferon (reaferona) and acyclovir in the treatment of experimental genital herpes in Guinea pigs [STD, 2, Wen solution immunologically active protein fraction of plasma or serum of human blood, containing IgG. [C. N. Serov, Herald an obstetrician-gynecologist, 3, 1997, S. 42-44].

Recently actively developing antibacterial and antiviral drugs based on antibodies.

Well-known drug for the treatment of viral, chlamydial and bacterial infections for rectal containing genetically engineered interferon and-tocopherol acetate [U.S. Pat. RF 2057544, a 61 K 38/21, from 10.04.96, bull. 10].

Of interest is the use of complex immunoglobulin preparation (TRC) with a high content of IgM, IgA and IgG by protein processing ballast fraction [New drugs, vol. 3, 1993, S. 16; U.S. Pat. RF 2051054, a 61 K 39/395, from 27.12.95. Bull. 36].

Closest to the claimed method is an approach to the treatment of PID polymicrobial etiology that involves antibiotic therapy, this combination of drugs selected depending on the type of bacteria (gram-positive and gram-negative), the nature of the inflammatory process [STD, 2, 1994, S. 7-11]. However, only the use of antibacterial or antiviral therapy leads to inhibition of immunological reactions, intracellular adaptation of microorganisms to the transfer of the infection in a latent Costea efficiency, shorter period of treatment, the increase magnetizing period.

The technical result is achieved by a method for the treatment of chlamydial PID-herpetic etiology includes a preliminary immunotherapy interferon within 7-10 days, antiviral drugs since 3-4 days immunotherapy, for 5-6 day - the introduction of antibiotics, hormone therapy with 5 to 25 days of the menstrual cycle for 3-6 months.

As interferons used complex immunoglobulin preparation with a high content of IgM, IgA and IgG and recombinant-2-interferon.

Distinctive features of the method are the following.

Prior immunotherapy complex immunoglobulin preparation and recombinant-2-interferon.

One of the main means of protecting the body from viral and bacterial infections is its own system of interferons, which are the main effector mechanism of cell-mediated immune response against the infection. When inadequate immune system function using recombinant-interferon-2 provides the inhibition of intracellular growth of bacteria, stimulating the E. antimicrobial and antiviral effects as intracellular, and in the extracellular environment of the organism.

Combination with immunotherapy antibiotic and antiviral therapy while suppressing ovulation and regulation of the hypothalamic-pituitary-ovarian relationships with hormonal drugs provides a stronger antiviral and protivodiareynoe action than using them separately without the use of immunotherapy.

Time periods stages of treatment established in clinical practice, their necessity and sufficiency confirmed by laboratory diagnosis (DFA, IFA, PCR) and indicators of immunological reactivity.

The opportunity for practical application of the proposed method is illustrated by an example of its specific implementation.

Example. Patient E., age 17, was admitted to the hospital 12.01.99, complaining of aching pain in the lower abdomen, itching and burning in the vulva. Somatic history is not burdened. Menstruation at the age of 13, after 28 days, 5 days, moderate, painless. Last month 20.12.98. Sex life since the age of 14, out of wedlock, for the entire period 8 sexual partners. Pregnancy one, ended artifactual abortion. From history revealed: ill 2 dniprovyh authorities in connection, what appealed to the LCD, directed, and hospitalized.

During examination: General condition is satisfactory, pulse 78 in 1 min, body temperature 36.8oC.

External genitals are developed correctly; at the posterior adhesions redness, swelling, tenderness to palpation, vesicles filled with clear content. Inspection in the mirror: the mucosa of the cervix erozirovanne in the circumference of the cervical canal with a diameter of 1.5 cm At vaginal examination: the body of the uterus in normal position, tight, limited is movable, painless. Appendages on both sides tyazhistye sensitive to palpation.

In smears from the urethra of the cervical canal by the method of the DFA, PCR detected chlamydia; in smears taken from the cervical canal and contents of vials, PCR detected HSV, ELISA blood - level HSV IgM positive.

Indicators of immunological indexes: content of EB-ROCK% slightly decreased to 4.5% (in the control 5,80,43%), the number of S ROCK a/h 0,11 (control 0,150,01); the content of T cells with helper activity 77% (in the control 51,21,4); the content of T-suppressor cells 4% (in the control 6,70,71); the ratio Th/TC 19,2 (control 6,720,92); the content of IgA to 3.09 g/l (control 1,670,07 g/l); conzatti, chlamydia, genital herpes.

Patient treatment: candles TRC-2-interferon in 500000 IU (1 candle) on the day rectal, on the third day of therapy was prescribed valtrex (valcyclovir) - 500 mg 2 times a day, for 5 days (at the rate of 5 g). On the 5th day showed complete epithelialization of the hearth herpes sores. With 5-6 days immunotherapy started antibiotics with protivodiareynoe activity: azithromycin (Sumamed) - a single dose of 500 mg for 6 days (at the rate of 3.0 g). In addition, the patient received vitamin therapy, physical therapy, was conducted in prevention of candidiasis. With 22.01.99 year (5th day of the menstrual cycle) is assigned a three-regol in the schematic.

At 4-5 days after initiation of therapy showed improvement in General condition, disappeared itching and burning in the vulva, on the 5th day showed complete epithelialization of the hearth herpes sores. For 8 days completely disappeared pain in the lower abdomen. On the 11th day the treatment was completed. Immunological parameters after treatment was: the content of the EB-ROCK% 6,0% (in the control 5,80,43%), the number of S ROCK a/h 0,15 (control 0,150,01); the content of T cells with helper activity 51,4% (in the control 51,21,4); the content of T-suppressor cells is 7.4% (in the 3,4 (control 3,20,18).

The patient was discharged from the hospital with full clinical recovery. 21 days after discontinuation of antibiotics, a study of the content of the cervical canal and the urethra by the method of DFA and PCR chlamydia is not detected. Follow-up research in 1.5 months by PCR chlamydia is not detected, ELISA detected only the titer of IgG, IgM level C. trachomatis negative. At the same time doing research on the presence of HSV. PCR diagnosis - HSV is not detected, ELISA: the level of HSV IgG positive, IgM level HSV - negative. During the period of follow-up studies of clinical symptoms and residual effects of the inflammatory process of the genitals is not found.

Further observation of the patient during 1 year 4 months showed complete absence of subjective and objective signs of previous inflammatory process in the small pelvis organs Mycoplasma-herpetic etiology.

Using the proposed method in terms of modern micro-social environment model of sexual behaviour related to risk factors such as early age of onset of promiscuity, multiple sexual partners, will improve the efficiency of cure chlamydial herpes infectiously etiology, wherein the immunotherapy complex immunoglobulinum drug-2-recombinant interferon in the form of candles for 7-10 days, antiviral agents appointed from 3-4 days immunotherapy for 4-5 days 5-6 days immunotherapy begin introduction protivodiareynah antibiotics within 6-10 days; at the same time spend hormone therapy monophasic, low-dose hormonal contraceptives: from 5 to 25 days of the menstrual cycle for 3-6 months.

 

Same patents:

The invention relates to medicine, Hepatology, to methods of treatment of chronic viral hepatitis
The invention relates to medicine, more specifically to oncourology, and may find application in the treatment of malignant tumors of the kidney with metastases
The invention relates to the venereal diseases and urology, and is intended for the integrated treatment of benign tumors of the urethra associated with urogenital infections

The invention relates to the field of the biotechnology industry, in particular the production of virus-inducer for the production of human leukocyte interferon
The invention relates to medicine, the pharmaceutical industry and relates to the creation of new dosage forms containing CLI
The invention relates to medicine, namely to physiotherapy
The invention relates to medicine, in particular to urology, and can be used for the treatment of benign prostatic hyperplasia
Remedy // 2172180
The invention relates to medicine, in particular to the pharmaceutical industry

The invention relates to medicine and can be used for the treatment of acute viral respiratory infections (ARI) in children

The invention relates to medicine, namely to methods of local treatment of rheumatic diseases of the joints

The invention relates to medicine and relates to compositions for the treatment of anorectal and colon-intestinal diseases

The invention relates to the medical industry, namely the production of medicines, containing four, pathcomponent mixture of acetylsalicylic acid, paracetamol, ascorbic acid, organic salts of calcium, Dimedrol, and(or) routine used for relief of acute manifestations of influenza

The invention relates to a new 9-N-ethenylene derivative 9 (S)-erythromycylamine General formula I, where R1and R2the same or different and represent a nitrile group, a carboxyl group of the formula COOR3where R3represents a C1-C4is an alkyl group, or ketogroup formula COR4where R4represents a C1-C4is an alkyl group, or of pharmaceutically acceptable salts of the accession of inorganic or organic acids, as well as to the method of production thereof

The invention relates to derivatives of erythromycin A, has antibiotic activity, suitable for the treatment of infectious diseases, in particular, the invention relates to derivatives of 9-[O-(aminoalkyl)oxime]of erythromycin A, has antibiotic activity against gram-positive and gram-negative microorganisms

The invention relates to new derivatives of erythromycin, method of production thereof, to pharmaceutical compositions based on them and to intermediate compounds
The invention relates to medicine, in particular infectious diseases, and for the prevention Ixodes tick-borne borreliosis

The invention relates to medicine and can be used to treat a variety of rhinitis: allergic, polynosic, year-round

The invention relates to medicine, in particular to urology and andrology

The invention relates to medicine, in particular to andrology and urology
Up!